Bio Protocol: Four AI-Designed Peptides Enter Wet-Lab Testing - Aug 2026

According to Bio Protocol's peptide testing announcement, four AI-designed peptides enter laboratory synthesis and testing on living cells targeting KISS1R and OX2R. The work moves these candidates from computational predictions into biological experiments during August 2026.The lab will first establish that the peptide sequences can be synthesized, then test whether each activates its target receptor, how strongly it does so, and whether it also affects unrelated receptors. These measurements provide a validation checkpoint for the design process and can guide subsequent model designs.The results remain pending, so entering testing confirms availability for evaluation rather than biological performance or adoption. Selectivity is a specific limitation: activity at unintended receptors could reduce the usefulness of a candidate even if it activates KISS1R or OX2R.Four molecules exist right now only as predictions on a computer.This month they go into a lab for the first time, and we find out whether the predictions were true.Here's what's actually being tested. 's agents designed two peptides for KISS1R, a receptor involved…